New Leaf Venture Partners’s Trillium Therapeutics Inc. TRIL Stock Holding History

New Leaf Venture Partners’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-404,159	Closed	-$2.91M	–	17
2018 Q1	$2.91M	Hold	404,159	–	–	1.57%	10
2017 Q4	$2.93M	Hold	404,159	–	–	1.37%	12
2017 Q3	$2.08M	Hold	404,159	–	–	0.97%	13
2017 Q2	$1.78M	Buy	404,159 +300,000	+288%	+$1.66M	1.25%	15
2017 Q1	$641K	Buy	104,159 +7,400	+8%	+$43.4K	0.33%	16
2016 Q4	$547K	Buy	96,759 +16,000	+20%	+$159K	0.39%	14
2016 Q3	$1.19M	Hold	80,759	–	–	0.86%	12
2016 Q2	$725K	Buy	+80,759	New	+$839K	0.62%	14

Other funds holding TRIL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

New Leaf Venture Partners's TRIL Position: Q2 2018 in Review

New Leaf Venture Partners sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2018, closing a stake of 404,159 shares — an estimated $2.91M sold.

New Leaf Venture Partners first reported a position in TRIL in Q2 2016 and held it in 8 quarters. The position peaked at $2.93M in Q4 2017. 29 funds tracked by Wall St. Rank hold TRIL as of Q2 2018.

New Leaf Venture Partners reported no remaining Trillium Therapeutics Inc. position as of Q2 2018 after selling out during the quarter.
New Leaf Venture Partners sold 404,159 Trillium Therapeutics Inc. shares in Q2 2018, an estimated $2.91M.
New Leaf Venture Partners first reported a position in Trillium Therapeutics Inc. in Q2 2016 and held it in 8 quarters.
New Leaf Venture Partners's Trillium Therapeutics Inc. position peaked at $2.93M in Q4 2017.
29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2018.

Based on New Leaf Venture Partners's 13F filing for Q2 2018, filed 14 Aug 2018.